Literature DB >> 25601352

Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.

Klaas Heinemann1, Suzanne Reed2, Sabine Moehner2, Thai Do Minh2.   

Abstract

OBJECTIVES: The objectives were to identify and compare the incidence of uterine perforation and other medically adverse events associated with levonorgestrel-releasing intrauterine systems (LNG-IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) under routine conditions of use in a study population representative of typical users. METHODS AND MATERIALS: This is a multinational, prospective, non-interventional cohort study with new users of LNG-IUSs and copper IUDs. In addition to a baseline questionnaire, women and their treating health care professional completed a single follow-up questionnaire after 12 months. All patient-reported outcomes were validated by the treating physicians.
RESULTS: A total of 61,448 women in six European countries were followed between 2006 and 2013 for more than 68,000 women-years of observation (70% LNG, 30% copper devices). Overall, 81 uterine perforations were reported: 61 for LNG-IUSs [1.4 per 1000 insertions (95% confidence interval {CI}: 1.1-1.8)] and 20 for copper IUDs [1.1 per 1000 insertions (95% CI: 0.7-1.7)], for an adjusted risk ratio (RRadj) of 1.6 (95% CI: 1.0-2.7) when adjusted for age, body mass index, breastfeeding at time of insertion and parity. Breastfeeding at time of insertion was associated with a sixfold increase (RR 6.1, 95% CI: 3.9-9.6), with no differences between LNG and copper IUD users. Sixty-three of the total 81 perforations were associated with previously suspected risk factors (e.g., breastfeeding, time since last delivery ≤36 weeks). No perforations led to serious illness or to injury of intra-abdominal or pelvic structures.
CONCLUSIONS: Uterine perforation incidence in this study was low, with a benign clinical course thereafter. The LNG-IUSs and copper IUDs did not have clinically important differences in perforation rates. IMPLICATIONS: The European Active Surveillance Study on Intrauterine Devices is the first large-scale, prospective, non-interventional study to compare the perforation risk in LNG-IUS and copper IUD users. It is the first to examine the independent roles that breastfeeding status and postpartum status have on perforation risk. Conducted during routine clinical practice, the findings are generalizable to broader populations.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Copper; Intrauterine device; Levonorgestrel; Uterine perforation

Mesh:

Substances:

Year:  2015        PMID: 25601352     DOI: 10.1016/j.contraception.2015.01.007

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  29 in total

1.  [Fever and renal failure in a 38-year-old woman].

Authors:  S Fitzner; A Gäfgen; A Franke; R Brunkhorst
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-02-11       Impact factor: 0.840

2.  Factors associated with postpartum use of long-acting reversible contraception.

Authors:  Titilope Oduyebo; Lauren B Zapata; Maegan E Boutot; Naomi K Tepper; Kathryn M Curtis; Denise V D'Angelo; Polly A Marchbanks; Maura K Whiteman
Journal:  Am J Obstet Gynecol       Date:  2019-03-15       Impact factor: 8.661

3.  Women's willingness and ability to feel the strings of their intrauterine device.

Authors:  Juliana Melo; Mary Tschann; Reni Soon; Melissa Kuwahara; Bliss Kaneshiro
Journal:  Int J Gynaecol Obstet       Date:  2017-04-08       Impact factor: 3.561

Review 4.  Imaging evaluation of uterine perforation and rupture.

Authors:  Hassan Aboughalia; Deepashri Basavalingu; Margarita V Revzin; Laura E Sienas; Douglas S Katz; Mariam Moshiri
Journal:  Abdom Radiol (NY)       Date:  2021-06-15

Review 5.  Family Planning and Rheumatoid Arthritis.

Authors:  Nicole Hunt; Mehret Birru Talabi
Journal:  Curr Rheumatol Rep       Date:  2019-03-06       Impact factor: 4.592

Review 6.  Eliminating health disparities in unintended pregnancy with long-acting reversible contraception (LARC).

Authors:  Caitlin Parks; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2016-02-12       Impact factor: 8.661

Review 7.  Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-11-01

8.  Hydronephrosis due to a Migrated Intrauterine Device into the Ureter: A Very Rare Case.

Authors:  Ibrahim Halil Bozkurt; Ismail Basmaci; Tarik Yonguc; Ozgu Aydogdu; Mehmet Erhan Aydin; Ertugrul Sefik; Tansu Degirmenci
Journal:  Eurasian J Med       Date:  2018-06-01

9.  Referral Center Experience With Nonpalpable Contraceptive Implant Removals.

Authors:  Melissa C Matulich; Melissa J Chen; Natasha R Schimmoeller; Jennifer K Hsia; Suji Uhm; Machelle D Wilson; Mitchell D Creinin
Journal:  Obstet Gynecol       Date:  2019-10       Impact factor: 7.661

10.  Efficacy and Safety of Long-Acting Reversible Contraception in Women With Cardiovascular Conditions.

Authors:  Quyen Vu; Elizabeth Micks; Erin McCoy; Sarah Prager
Journal:  Am J Cardiol       Date:  2015-11-05       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.